|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lara PN Jr, Chansky K, Shibata T, Fukuda
H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N and Gandara
DR: Common arm comparative outcomes analysis of phase 3 trials of
cisplatin + irinotecan versus cisplatin + etoposide in extensive
stage small cell lung cancer: Final patient-level results from
Japan Clinical Oncology Group 9511 and Southwest Oncology Group
0124. Cancer. 116:5710–5715. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luqmani YA: Mechanisms of drug resistance
in cancer chemotherapy. Med Princ Pract. 14 Suppl 1:S35–S48. 2005.
View Article : Google Scholar
|
|
6
|
Chekanova JA and Belostotsky DA: MicroRNAs
and messenger RNA turnover. Methods Mol Biol. 342:73–85.
2006.PubMed/NCBI
|
|
7
|
Martello G, Rosato A, Ferrari F, Manfrin
A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T,
et al: A MicroRNA targeting dicer for metastasis control. Cell.
141:1195–1207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mo YY: MicroRNA regulatory networks and
human disease. Cell Mol Life Sci. 69:3529–3531. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ladeiro Y, Couchy G, Balabaud C,
Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J:
MicroRNA profiling in hepatocellular tumors is associated with
clinical features and oncogene/tumor suppressor gene mutations.
Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ge YZ, Xin H, Lu TZ, Xu Z, Yu P, Zhao YC,
Li MH, Zhao Y, Zhong B, Xu X, et al: MicroRNA expression profiles
predict clinical phenotypes and prognosis in chromophobe renal cell
carcinoma. Sci Rep. 5:103282015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Li M, Han Y, Hong L, Gong T, Sun
L and Zheng X: Down-regulation of miR-27a might reverse multidrug
resistance of esophageal squamous cell carcinoma. Dig Dis Sci.
55:2545–2551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
El-Khoury V, Breuzard G, Fourre N and
Dufer J: The histone deacetylase inhibitor trichostatin A
downregulates human MDR1 (ABCB1) gene expression by a
transcription-dependent mechanism in a drug-resistant small cell
lung carcinoma cell line model. Br J Cancer. 97:562–573. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hodkinson PS, Mackinnon AC and Sethi T:
Extracellular matrix regulation of drug resistance in small-cell
lung cancer. Int J Radiat Biol. 83:733–741. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yeh JJ, Hsu NY, Hsu WH, Tsai CH, Lin CC
and Liang JA: Comparison of chemotherapy response with
P-glycoprotein, multidrug resistance-related protein-1, and lung
resistance-related protein expression in untreated small cell lung
cancer. Lung. 183:177–183. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cichy J, Kulig P and Puré E: Regulation of
the release and function of tumor cell-derived soluble CD44.
Biochim Biophys Acta. 1745:59–64. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peifer M, Fernández-Cuesta L, Sos ML,
George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander
T, et al: Integrative genome analyses identify key somatic driver
mutations of small-cell lung cancer. Nat Genet. 44:1104–1110. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rudin CM, Durinck S, Stawiski EW, Poirier
JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory
J, et al: Comprehensive genomic analysis identifies SOX2 as a
frequently amplified gene in small-cell lung cancer. Nat Genet.
44:1111–1116. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hoefer J, Kern J, Ofer P, Eder IE, Schäfer
G, Dietrich D, Kristiansen G, Geley S, Rainer J, Gunsilius E, et
al: SOCS2 correlates with malignancy and exerts growth-promoting
effects in prostate cancer. Endocr Relat Cancer. 21:175–187. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong S, Hwang I, Lee YS, Park S, Lee WK,
Fernandes-Alnemri T, Alnemri ES, Kim YS and Yu JW: Restoration of
ASC expression sensitizes colorectal cancer cells to genotoxic
stress-induced caspase-independent cell death. Cancer Lett.
331:183–191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abusnina A, Alhosin M, Keravis T, Muller
CD, Fuhrmann G, Bronner C and Lugnier C: Down-regulation of cyclic
nucleotide phosphodiesterase PDE1A is the key event of p73 and
UHRF1 deregulation in thymoquinone-induced acute lymphoblastic
leukemia cell apoptosis. Cell Signal. 23:152–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yan R, Shi Q, Hu X and Zhou X: Reticulon
proteins: emerging players in neurodegenerative diseases. Cell Mol
Life Sci. 63:877–889. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Du L and Pertsemlidis A: microRNA
regulation of cell viability and drug sensitivity in lung cancer.
Expert Opin Biol Ther. 12:1221–1239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cherni I and Weiss GJ: miRNAs in lung
cancer: Large roles for small players. Future Oncol. 7:1045–1055.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao X, Yang L and Hu J: Down-regulation
of miR-27a might inhibit proliferation and drug resistance of
gastric cancer cells. J Exp Clin Cancer Res. 30:552011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tian Y, Fu S, Qiu GB, Xu ZM, Liu N, Zhang
XW, Chen S, Wang Y, Sun KL and Fu WN: MicroRNA-27a promotes
proliferation and suppresses apoptosis by targeting PLK2 in
laryngeal carcinoma. BMC Cancer. 14:6782014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li J, Wang Y, Song Y, Fu Z and Yu W:
miR-27a regulates cisplatin resistance and metastasis by targeting
RKIP in human lung adenocarcinoma cells. Mol Cancer. 13:1932014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Duan Y, Hu L, Liu B, Yu B, Li J, Yan M, Yu
Y, Li C, Su L, Zhu Z, et al: Tumor suppressor miR-24 restrains
gastric cancer progression by downregulating RegIV. Mol Cancer.
13:1272014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Gu X, Li Z, Xiang J, Jiang J and
Chen Z: microRNA expression profiling in multidrug resistance of
the 5-Fu-induced SGC7901 human gastric cancer cell line. Mol Med
Rep. 7:1506–1510. 2013.PubMed/NCBI
|
|
34
|
Liang J, Liu X, Xue H, Qiu B, Wei B and
Sun K: MicroRNA-103a inhibits gastric cancer cell proliferation,
migration and invasion by targeting c-Myb. Cell Prolif. 48:78–85.
2015. View Article : Google Scholar : PubMed/NCBI
|
